The roles of the carboxyl-terminal tail of the ␣ 1B -adrenergic receptor in its expression, function, and regulation were investigated by site-directed mutagenesis. The receptor construct truncated after residue 363 seemed not to be properly expressed. In contrast, the receptor truncated after residue 366 and all of the longer receptor constructs were properly expressed and exhibited agonist and antagonist binding and activation of phosphoinositide hydrolysis similar to the wild-type receptor. Agonist-induced sequestration of receptors within the plasma membrane, endocytosis into intracellular vesicles, and eventual down-regulation were all absent in the receptor truncated after residue 366. A series of sequential truncations and a deletion mutation identified a critical role for residues 403 to 425, which include the previously identified sites for G proteincoupled receptor kinase phosphorylation, in agonist-induced internalization of the receptor. Similar studies identified a critical role for residues 367 to 380 in agonist-induced downregulation. Individual point mutations converting either cysteine 367 or serine 369 to alanine selectively eliminated down-regulation, thus identifying two specific amino acid residues required for down-regulation. Importantly, several of the mutated receptors that failed to show rapid agonist-induced internalization nonetheless exhibited normal agonist-induced down-regulation. In addition to identifying specific regions and individual residues of the ␣ 1B -adrenergic receptor involved in internalization and down-regulation, these studies provide mutated receptors that internalize but do not down-regulate, that downregulate without internalization, and that are defective in both internalization and down-regulation, all of which should be useful tools for further studies of the specific cellular compartments and molecular mechanisms involved in receptor internalization and down-regulation.
cal role for residues 367 to 380 in agonist-induced downregulation. Individual point mutations converting either cysteine 367 or serine 369 to alanine selectively eliminated down-regulation, thus identifying two specific amino acid residues required for down-regulation. Importantly, several of the mutated receptors that failed to show rapid agonist-induced internalization nonetheless exhibited normal agonist-induced down-regulation. In addition to identifying specific regions and individual residues of the ␣ 1B -adrenergic receptor involved in internalization and down-regulation, these studies provide mutated receptors that internalize but do not down-regulate, that downregulate without internalization, and that are defective in both internalization and down-regulation, all of which should be useful tools for further studies of the specific cellular compartments and molecular mechanisms involved in receptor internalization and down-regulation.
Agonist binding to G protein-coupled receptors (GPCRs) leads not only to their activation and the generation of intracellular responses but also to adaptive changes in the receptors that limit their subsequent responsiveness. These receptor-specific changes include a rapid uncoupling of receptors from activation of their cognate G proteins, mediating functional desensitization; a rapid redistribution of receptors into relatively inaccessible compartments in the plasma membrane or inside the cell, variously referred to as sequestration, endocytosis, or internalization; and a slower loss of radioligand binding sites with prolonged agonist exposure, termed down-regulation (Perkins et al., 1991) . Considerable progress has been made in recent years in identifying the receptor modifications involved in these changes for the prototypical ␤ 2 -adrenergic receptor (␤ 2 AR) and various other receptors (Ferguson et al., 1996; Bohm et al., 1997; Krupnick and Benovic, 1998) , although many of the details of the molecular modifications and protein-protein interactions that are involved in bringing about these changes remain to be determined.
Recent studies have focused on the role of the carboxylterminal tail of GPCRs in mediating these adaptive changes. For many GPCRs, the carboxyl-terminal tail seems to be required for functional desensitization and/or for internalization, as well as for the receptor phosphorylation that is thought to play an important role in mediating both desensitization and internalization. In addition to the extensive studies with ␤ 2 ARs cited above, carboxyl-terminal tail involvement has been documented for other G s -coupled receptors such as H 2 histamine receptors (Fukushima et al., 1997) , for G i -coupled receptors such as SSTR3 (Roth et al., 1997) , and for G q -coupled receptors such as P2Y 2 nucleotide receptors (Garrad et al., 1998) , to cite only a few examples. The receptor sequences and molecular mechanisms involved in GPCR internalization have received considerable recent attention. However, much less is known about the role of the carboxyl-terminal tail or other receptor domains in the receptor down-regulation that occurs with long-term agonist treatment, which remains the most poorly understood of the adaptive changes that occur after agonist activation of GPCRs. However, a few studies have implicated specific carboxyl-terminal tail residues in down-regulation of GPCRs as well, including G s -coupled ␤ 2 ARs (Valiquette et al., 1990) , G i -coupled ␦-opioid receptors (Cvejic et al., 1996) , and G qcoupled m3 muscarinic acetylcholine receptors (Yang et al., 1993) .
Similar to other GPCRs, ␣ 1B ARs also undergo agonistinduced desensitization, internalization, and down-regulation (Hoffman, 1987; Toews et al., 1991; Cotecchia et al., 1995; Bird et al., 1997) , although there are differences in the extent to which these processes occur among the various systems that have been studied. In cultured cell systems, functional desensitization of ␣ 1B ARs can be induced by agonists or by protein kinase C-activating phorbol esters, and desensitization is accompanied by receptor phosphorylation (Leeb-Lundberg et al., 1985 . Internalization of ␣ 1B ARs occurs, although the extent to which sequestration within the plasma membrane versus endocytosis into intracellular vesicles contribute to internalization and the effects of protein kinase C activators on these changes appear to be cell typespecific (Leeb-Lundberg et al., 1987; Toews, 1987; Cowlen and Toews, 1988; Zhu et al., 1996) . We have obtained a range of results in our studies of long-term regulation of ␣ 1B AR expression, with down-regulation, no down-regulation, or even up-regulation occurring in different cell types or in different clones of ␣ 1B AR-transfected cells (Toews, 1987; Zhu et al., 1996; Bird et al., 1997) .
The functional domains of the ␣ 1B AR mediating desensitization and internalization are beginning to be elucidated. A previous study showed that truncation of most of the carboxyl-terminal tail of the ␣ 1B AR prevented its phosphorylation and desensitization and slowed its internalization after agonist exposure (Lattion et al., 1994) . A subsequent study identified multiple specific carboxyl-terminal tail serine residues involved in phosphorylation and functional desensitization of the ␣ 1B AR in response to both agonists and protein kinase C activators (Diviani et al., 1997) . However, the specific carboxyl-terminal tail sequences involved in ␣ 1B AR internalization and down-regulation have not been determined. In these studies, we have generated ␣ 1B ARs with truncations, deletions, and individual point mutations within the carboxylterminal tail to identify the ␣ 1B AR sequences involved in agonist-induced internalization and down-regulation. Our results indicate that both processes require sequences within the carboxyl-terminal tail of the receptor, but that the regions involved in these two processes are distinct. Our results further demonstrate that down-regulation can occur even for receptors that fail to exhibit rapid receptor internalization.
Experimental Procedures
Materials. Cell culture medium, serum, trypsin, G418, and LipofectAMINE reagent were obtained from Life Technologies (Grand Island, NY Site-Directed Mutagenesis. The cDNA encoding the ␣ 1B AR was cleaved from the plasmid pRC/CMV at the HindIII/XbaI sites and subcloned to phage M13 mp18 also digested with HindIII/XbaI, and mutations to the coding sequence were then generated by oligonucleotide-directed mutagenesis using the Bio-Rad Muta-Gene M13 Kit, all as in our previous study (Wang et al., 1997) .
The mutagenic primers for the truncation mutants were as follows, where the underlined nucleotides represent the stop codon that was introduced: ATGCGTATCCTTTAGTGCCAGTGCCGT for the receptor truncated after Leu363 (Tr363); CTTGGGTGCCAG-TAGCGTAGTGGCCGT for the receptor truncated after Gln366 (Tr366); CGTCGTCTGGGCTAGGCGTGCGCTTAC for the receptor truncated after Gly380 (Tr380); CAGTCGCGGAAGTAGGACTC-CCTGGAC for the receptor truncated after Lys402 (Tr402); GCGTCGCCCAGCTAGCCGGGCTACCTG for the receptor truncated after Ser425 (Tr425); AAATCCGGGGCTTAGCTGCTCAG-TCTG for the receptor truncated after Ala449 (Tr449); and CTCTT-GGGAGAGTAGCCGGAGAGCCCG for the receptor truncated after Pro477 (Tr477). For Tr363 and Tr366, the TAG stop codon was substituted for the following amino acid normally present; for the other truncations, the TAG stop codon was inserted ahead of the following amino acid normally present. The mutagenic primers for the deletion mutants were as follows (the carat represents the site at which the deletion was introduced): ATCCTTGGGTGCCAGˆGCGT-GCGCTTACACC for Del [367] [368] [369] [370] [371] [372] [373] [374] [375] [376] [377] [378] [379] [380] , deleting residues 367 through 380, and TCGCAGTCGCGGAAGˆCCGGGCTACCTGGGT for Del , deleting residues 403 through 425. The mutagenic primers for the two point mutations were as follows, where the underlined nucleotides represent the altered amino acid: CTTGGGT-GCCAGGCTCGTAGTGGCCGT for the receptor with Ala substituted for Cys367 (C367A); and TGCCAGTGCCGTGCAGGCCGTCGCCGC for the receptor with Ala substituted for Ser369 (S369A).
After confirmation of the mutations by DNA sequencing, the mutated ␣ 1B ARs were cut from M13 mp18 using HindIII/XbaI and subcloned into the expression vector pRC/CMV, followed by DNA sequencing to reconfirm the mutation. The wild-type and mutated ␣ 1B AR plasmids were then stably transfected into CHO-K1 Chinese hamster ovary cells using LipofectAMINE, and clones resistant to 400 g/ml G418 were isolated and screened for ␣ 1B AR expression, as in our previous study (Wang et al., 1997) .
Cell Culture. Cells were maintained in monolayer culture in Ham's F12 medium supplemented with 10% fetal bovine serum and 200 g/ml G418 at 37°in a humidified incubator with a 5% CO 2 atmosphere. Cells from confluent flasks were trypsinized and plated in culture dishes at 3000 to 5000 cells/cm 2 . Cells were typically used for experiments on the fourth day of culture.
Radioligand Binding Assays. For membrane preparation, cells grown on 150-mm dishes were rinsed twice with 10 ml of ice-cold wash buffer (10 mM Tris, pH 7.4, 140 mM NaCl) and then twice with 10 ml of ice-cold lysis buffer (1 mM Tris, pH 7.4, 2 mM EDTA) and allowed to swell for 10 min on ice. Cells were then lysed by scraping from the dish with a rubber policeman. The lysate was centrifuged for 30 min at 20,000 rpm in an SM24 rotor in a Sorvall RC5B refrigerated centrifuge. The membrane pellet was resuspended in binding buffer (20 mM Tris, pH 7.4, 2 mM MgCl 2 , 140 mM NaCl) with a Tissumizer (Tekmar, Cincinnati, OH), and this membrane suspension was used in radioligand binding assays. Membranes were incubated with [ 3 H]prazosin in binding buffer for 60 min at 37°i n a shaking water bath. The reactions were stopped by filtration over Whatman GF/B glass fiber filters on a Brandel (Gaithersburg, MD) cell harvester and washing three times with 4 ml of wash buffer. Liquid scintillation counting was used to quantify radioactivity associated with the filters. Labeled compounds were then extracted from the cells with methanol, and chloroform and water were added, as described (Nakahata et al., 1986) . Inositol phosphates in the resulting aqueous phase were separated on Dowex 1-X8 (formate form) columns. Total inositol phosphates were eluted with 8 ml of 1 M ammonium formate and 0.1 M formic acid. Radioactivity in a 3-ml portion of the eluate (a) and a 0.375-ml portion of the organic phase containing the inositol phospholipids (b) were determined by liquid scintillation counting. The percentage of conversion of inositol phospholipids to inositol phosphates was then calculated by the formula a / (a ϩ b) ϫ 100%. Cell Surface Accessibility of Receptors by Assays of Radioligand Binding on Ice. Cells in growth medium on 35-mm dishes were exposed to 10 M epinephrine plus 1 mM ascorbate for 30 min at 37°to induce redistribution. Control cells were exposed only to the 1 mM ascorbate vehicle. Cells were rinsed twice with 2 ml of Ham's-HEPES and then incubated on ice for 4 h with 1.8 nM [
3 H]prazosin in Ham's-HEPES. Cells were then rinsed twice with 2 ml of Ham's-HEPES containing 10 M phentolamine to remove unbound radioligand and dissolved in 1 ml of 0.2 N NaOH. Radioactivity associated with the dissolved cells was assessed by liquid scintillation counting. Nonspecific binding was defined as that occurring in the presence of 10 M phentolamine.
Receptor Redistribution by Sucrose Density Gradient Centrifugation Assays. Cells grown on 100-mm dishes were given fresh growth medium on the day before the experiment. Cells were exposed to 10 M epinephrine or vehicle for 30 min at 37°to induce internalization. Cells were rinsed twice with 10 ml of ice-cold wash buffer and then twice with ice-cold lysis buffer and allowed to swell for 10 min on ice. Cells were then lysed by scraping from the dishes in 0.8 ml of lysis buffer with a rubber policeman. This lysate was layered on top of a discontinuous sucrose density gradient consisting of 1.7 ml of 15% sucrose, 5.0 ml of 30% sucrose, and 2.5 ml of 60% sucrose. Samples were centrifuged at 28,000 rpm for 60 min at 4°in an SW41 rotor in a Beckman L8-70 refrigerated ultracentrifuge. Fractions of 0.8 ml each were then collected from the top of the tubes. Binding of [ 3 H]prazosin (1.4 nM) to the membranes in each fraction was then determined essentially as described above.
Down-Regulation Assays. For down-regulation assays, cells grown on 100-mm dishes were incubated in the absence or presence of 10 M epinephrine for 24 h at 37°. Cells were then rinsed and lysed as for sucrose gradient assays. Centrifugation and resuspension of the membranes and binding of [ 3 H]prazosin (3.7 nM) to the isolated membranes were then conducted as described in Radioligand Binding Assays, above. In most cases, binding assays were conducted on the day that the membranes were isolated; however, for some experiments, the membrane pellets were stored at Ϫ80°C for a few days before resuspension and assay.
Data Analysis. Nonlinear regression analyses of saturation and competition binding assay and dose-response curve data were performed with GraphPad PRISM (GraphPad Software, Inc., San Diego, CA). Values for all parameters for all mutations are the averages of a minimum of three values determined in duplicate or triplicate, including assays with at least two different clones and performed on at least two different days. Data are presented as the mean Ϯ S.E. (n ϭ x, y), where x indicates the total number of determinations and y represents the number of different clones tested. Statistical comparisons of data for all of the mutated receptors to those for the wild-type receptor were by one-way ANOVA followed by Dunnett's multiple comparison test using GraphPad Prism (GraphPad Software), with statistically significant difference from the wild-type receptor taken at P Ͻ .05.
Results
Site-directed mutagenesis was used to generate hamster ␣ 1B ARs with truncations, deletions, and individual point mutations in their carboxyl-terminal tails (Fig. 1) . The characteristics of each mutated receptor were determined after stable transfection into Chinese hamster ovary cells. Receptor expression levels and antagonist binding affinities were 3 H]prazosin binding on ice as a measure of cell surface accessibility and the other measuring the percentage of the receptors that shift from the plasma membrane fraction to the light vesicle fraction on sucrose density gradients as a measure of endocytosis into intracellular vesicles. Both assays were used based on our previous studies with the ␣ 1B AR, which showed that agonist exposure could cause these receptors to lose their cell surface accessibility but remain plasma membraneassociated, presumably by becoming sequestered in a specialized compartment within the plasma membrane but not endocytosed into intracellular vesicles (Cowlen and Toews, 1988; Wang et al., 1997) . Down-regulation was assessed by measuring [ 3 H]prazosin binding to membrane preparations from cells pretreated for 24 h in the absence or presence of 10 M epinephrine. The results from these assays are summarized below for each of the sets of mutations that were generated.
Initial Truncation Mutations.
Previous studies found that truncation of the hamster ␣ 1B AR after Arg368 (Tr368 mutant) (thus deleting most of the carboxyl-terminal tail) generated a receptor with binding and functional properties similar to those of the wild-type receptor but with marked defects in agonist-induced receptor phosphorylation and desensitization and a slowed rate of internalization (Lattion et al., 1994) . In our initial mutagenesis, we generated two shorter ␣ 1B AR constructs to determine whether the more membrane-proximal portion of the carboxyl-terminal tail was important for receptor expression, binding, or function. The Tr366 receptor, truncated after Gln366, was expressed at levels similar to the wild-type receptor and exhibited binding and functional properties similar to the wild-type receptor (Table 1 ) but was completely defective in agonist-induced sequestration, endocytosis, and down-regulation (Fig. 2) a Values are the range of receptor expression levels in picomoles per milligram of membrane protein from both saturation and down-regulation assays for which membrane protein concentrations were determined.
b Competition data were fitted to both one-and two-site models; for all of the receptor constructs, the one-site fit was preferred. Data were also fitted to a variable slope model; the Hill coefficient for the wild-type receptor was 0.76 Ϯ 0.05 and the range for the mutated receptors was from 0.73 to 0.92, none of which was significantly different from the wild-type receptor. 
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Tr363 cDNA was expressed similarly to wild-type cDNA, suggesting that the defect in expression of the Tr363 receptor is post-transcriptional.
Sequential Truncations. The results with the Tr366 receptor clearly implicated the carboxyl-terminal tail of the ␣ 1B AR in its sequestration, endocytosis, and down-regulation. To delineate in more detail the regions of the carboxylterminal tail involved in each of these processes, we first generated a series of receptors with sequential truncations of the carboxyl-terminal tail (Fig. 1) : Tr477, truncated after Pro477; Tr449, truncated after Ala449; Tr425, truncated after Ser425; Tr402, truncated after Lys402; and Tr380, truncated after Gly380. All of these receptor constructs were expressed at high levels similar to those for the wild-type receptor (Table 1) ; no consistent differences in regulatory properties were observed between the higher and lower expressing clones. In saturation binding assays with isolated membrane preparations, K D values for [ 3 H]prazosin ranged from 37 to 68 pM, similar to the K D value of 43 pM for the wild-type receptor (Table 1) . Similarly, in the competition binding assays (Table 1) , all of the truncated receptors exhibited single-site K i values for epinephrine between 2.0 and 4.6 M, similar to the value of 2.0 M for the wild-type receptor.
All of the truncated receptors were functional in assays of epinephrine-stimulated PI hydrolysis, with fold-stimulation values ranging from 2.5-to 9.9-fold, compared with 4.4-fold stimulation for the wild-type receptor (Table 1 ). There was no clear indication of constitutive activity for any of the mutated receptors, although detailed studies of the correlation of basal or stimulated PI hydrolysis values for specific clones of each mutation with the corresponding levels of receptor expression in those clones were not undertaken. The potencies of epinephrine for stimulation of PI hydrolysis were somewhat variable among the mutated receptors, with EC 50 values ranging from 21 pM for Tr366 to 158 pM for Tr380 compared with the value of 43 pM for the wild-type receptor. The differences were not statistically significant, and there was no obvious correlation between the EC 50 values and the extent of truncation of the carboxyl-terminal tail. The higher potencies of epinephrine in functional assays of PI hydrolysis than in the competition binding assays most likely result from the presence of spare receptors or receptor reserve caused by the high levels of receptor expression in these transfected cells. However, the different experimental conditions for these two assays may also contribute to the observed differences.
In assays of agonist-induced receptor internalization (Fig.  2, top and middle) , Tr477, Tr449, and Tr425 all exhibited values similar to those for the wild-type receptor in both assays, with approximately 20 to 30% of the original cell surface receptors becoming inaccessible for [ 3 H]prazosin binding on ice and a similar percentage of the original plasma membrane receptors shifting to the light vesicle fraction on sucrose gradients. Both assays for internalization gave somewhat lower values than wild-type for Tr477 and somewhat higher values than wild-type for Tr425. In contrast, the shorter receptors Tr402 and Tr380 were almost completely defective in internalization in both assays, similar to the results with the Tr366 receptor. These results suggest that residues 403 to 425 of the ␣ 1B AR are required for its agonist-induced internalization.
In assays of down-regulation for the truncated receptors (Fig. 2, bottom ) , the Tr477 receptor, the longest of the truncated receptors, was markedly defective; Tr477 down-regulated by only 8%, compared with 39% down-regulation for the wild-type receptor. Surprisingly, the shorter receptors Tr449, Tr425, Tr402, and Tr380 all down-regulated well, with Tr449 and Tr402 down-regulating to a somewhat greater extent than the wild-type receptor and Tr425 and Tr380 downregulating somewhat less than the wild-type receptor. The observation of nearly normal down-regulation with Tr380 and the complete lack of down-regulation with Tr366 suggest that residues 367 to 380 of the ␣ 1B AR are important for its agonist-induced down-regulation. Sequences in the more distal part of the carboxyl-terminal tail may also be involved in Deletion Mutations. Results from the sequential truncation mutations suggested that residues 403 to 425 and 367 to 380 contain sequences critical for internalization and downregulation, respectively. However, it was also possible that these specific sequences are not required, but rather that a certain length of the carboxyl-terminal tail is required, independent of the specific amino acid sequence. To test the roles of the 403-to-425 and 367-to-380 regions in the context of a more normal carboxyl-terminal tail, we generated deletion mutations eliminating these sequences from an otherwise full-length receptor. Both the Del and Del [367] [368] [369] [370] [371] [372] [373] [374] [375] [376] [377] [378] [379] [380] receptors were expressed at levels comparable to the wild-type receptor ( (Table 1) . Del exhibited approximately 4-fold lower affinity than the wild-type receptor for binding of the agonist epinephrine, whereas epinephrine binding for Del [367] [368] [369] [370] [371] [372] [373] [374] [375] [376] [377] [378] [379] [380] was the same as for wildtype (Table 1 ). The epinephrine potencies and fold stimulation values for PI hydrolysis were not significantly different from those for the wild-type and truncated receptors (Table  1) . Thus neither of these regions is critical for agonist or antagonist binding or for receptor activation.
In agreement with the results from the sequential truncations, Del was completely defective in both assays for internalization but down-regulated at least as well as the wild-type receptor (Fig. 3) . These results confirm an important role for residues 403 to 425 in mediating rapid receptor internalization. In addition, they suggest that neither these specific residues nor rapid receptor internalization are required for the receptor down-regulation that occurs during long-term agonist exposure. Also in agreement with results from the sequential truncations, Del [367] [368] [369] [370] [371] [372] [373] [374] [375] [376] [377] [378] [379] [380] was markedly defective in down-regulation (Fig. 3) , exhibiting only 4.5% down-regulation, 12% of the down-regulation observed with the wild-type receptor. Del [367] [368] [369] [370] [371] [372] [373] [374] [375] [376] [377] [378] [379] [380] was clearly able to undergo agonist-induced internalization assessed by both assays; the extent of internalization was somewhat lower than that for wild-type in both assays, although the differences were not statistically significant (Fig. 3) .
Point Mutations. To further investigate individual residues within the 367-to-380 domain that are involved in down-regulation, we mutated Cys367 and Ser369 to Ala (C367A and S369A, respectively; Fig. 1 ). The C367A receptor exhibited binding affinities for [
3 H]prazosin and for epinephrine that were similar to those for the wild-type receptor, whereas S369A exhibited somewhat lower affinities for both ligands (Table 1) . Both C367A and S369A stimulated PI hydrolysis with similar potencies and fold-stimulation values as for the wild-type and other mutated receptors (Table 1) . Strikingly, both of these individual amino acid mutations generated receptors that were completely defective in downregulation with little or no defect in internalization (Fig. 3) .
Discussion
These studies identify distinct domains of the ␣ 1B AR carboxyl-terminal tail involved in agonist-induced internalization and down-regulation. Together with previous studies investigating receptor phosphorylation and functional desensitization (Lattion et al., 1994; Diviani et al., 1997) , our results indicate that the carboxyl-terminal tail is critical for all of the well-characterized adaptive changes in the ␣ 1B AR that occur after agonist exposure. In contrast, none of the carboxyl-terminal tail mutations caused marked alterations in receptor expression, binding or function, except for Tr363, the shortest construct, which prevented functional receptor expression.
The initial focus of our studies was to identify regions of the carboxyl-terminal tail mediating receptor internalization, including both sequestration within the plasma membrane and endocytosis into intracellular vesicles. None of the carboxyl-terminal tail mutations generated in this study had differential effects on sequestration versus endocytosis like those observed with the Y348A ␣ 1B AR in our previous study (Wang et al., 1997) ; all were either similar to wild-type for both responses or were essentially completely defective in both responses. Our results clearly demonstrate that residues 403 to 425 of the ␣ 1B AR are required for normal agonistinduced receptor internalization measured by either assay. Both the ability of Tr425 but not Tr402 to internalize normally and the selective loss of internalization in Del support this conclusion. This region of the receptor contains the serine residues at positions 404, 408, and 410 that have recently been identified as the sites required for GPCR kinase (GRK)-mediated phosphorylation and functional desensitization of the ␣ 1B AR (Diviani et al., 1997) . For the ␤ 2 AR, GRK-mediated phosphorylation has been shown to promote binding of ␤-arrestin to the receptor, which prevents functional coupling of the receptor with its G-protein, thus causing desensitization (Ferguson et al., 1996; Krupnick and Benovic, 1998) . More recently, ␤-arrestin bound to phosphorylated receptors has been shown to also serve as an adaptor protein linking the desensitized receptors to the clathrinmediated endocytosis machinery (Krupnick and Benovic, 1998) . Specific carboxyl-terminal tail serine and threonine residues or regions containing such residues have been shown to be required for internalization of several other GPCRs, with m3 muscarinic acetylcholine receptors (Yang et al., 1995) , AT 1a angiotensin receptors (Thomas, 1999) , and bradykinin receptors (Pizard et al., 1999) as examples for G q -coupled receptors. Based on these studies, it seems likely that the presence of the GRK phosphorylation sites in the 403-to-425 region accounts for the requirement of this region for agonist-induced internalization.
Although the mechanisms involved in GPCR internalization are beginning to be understood, much less is known about the molecular mechanisms or specific receptor sequences involved in GPCR down-regulation. Although we have observed little or no down-regulation (Toews, 1987) and even up-regulation of ␣ 1B ARs (Zhu et al., 1996; Bird et al., 1997) in some of our previous studies, 30 to 40% downregulation is the most typical result for transfected ␣ 1B ARs (Bird et al., 1997) , and this extent of down-regulation was consistently observed for the wild-type receptor in the current studies.
The ability of Tr380 but not Tr366 to undergo normal down-regulation as well as the relatively selective loss of down-regulation in Del [367] [368] [369] [370] [371] [372] [373] [374] [375] [376] [377] [378] [379] [380] clearly implicate residues 367 to 380 of the ␣ 1B AR in its agonist-induced down-regulation. This region contains at least three features of potential interest: Cys367, a potential site of receptor palmitoylation; Ser369, a potential site of receptor phosphorylation; and a string of consecutive Arg residues (eight in the ␣ 1B AR) that is found in the ␣ 1B AR and the ␣ 1D AR but not in the ␣ 1A AR or many other GPCRs. The studies presented here indicate that both the Cys367 and Ser369 residues are critical for downregulation, because mutation of either residue to Ala essentially completely eliminated down-regulation.
Palmitoylation of Cys367 is a reasonable candidate for the role of this region in down-regulation, because there is evidence for palmitoylation playing a role in down-regulation of ␣ 2A ARs (Eason et al., 1994) . Whether the ␣ 1B AR is palmitoylated, whether Cys367 or Cys365 (or both) is the site of palmitoylation, and the significance of palmitoylation for down-regulation or other aspects of ␣ 1B AR function are all areas for further study. Phosphorylation of Ser369 is also a reasonable mechanism for involvement in down-regulation, because this serine is close to basic amino acids on both its amino-and carboxyl-terminal sides and should be a good phosphorylation site for protein kinase C (Newton, 1995) . Interestingly, a recent study of down-regulation of the glucose-dependent insulinotropic peptide receptor also indicated that both the cysteine residue at the potential palmitoylation site and a nearby serine residue were involved in its downregulation (Tseng and Zhang, 1998) . Finally, a recent study suggests the possibility that the arginine string of the ␣ 1B AR could also be involved in down-regulation. This study showed that the arginine string was required for association of the ␣ 1B AR with a protein termed gC1q-R (the receptor for the globular heads of the C1q protein) and that over-expression of gC1q-R down-regulated expression of the ␣ 1B AR (Xu et al., 1999) . Thus it is possible that Cys367, Ser369, and the arginine string could all play important roles in agonist-induced down-regulation.
Our data suggest that the distal portion of the ␣ 1B AR carboxyl-terminal tail may also be important for down-regulation, based on the properties of the Tr477 and Tr449 receptors. The marked decrease in down-regulation with truncation at residue 477 and the recovery of down-regulation with further truncation to residue 449 can be explained if a downregulation-inhibiting domain is present between residues 450 to 477 and if the inhibitory activity of this domain is normally blocked by a counter-regulatory domain present between residues 478 to 515. Truncation at residue 477 would then unmask the inhibitory domain and decrease down-regulation, whereas further truncation to residue 449 would remove the inhibitory domain and restore down-regulation. There is precedent for this idea, because previous studies have reported both positive and negative signals for down-regulation in the carboxyl-terminal tails of ␤ARs (Hertel et al., 1990 ) and H 2 histamine receptors (Smit et al., 1996) .
The ability of receptors that are defective in internalization to nonetheless down-regulate normally, as seen for Tr402, Tr380 and Del , was an unexpected outcome of our studies. A study with ␤ 2 ARs also described mutations that allowed normal down-regulation without receptor internalization . Most current models assume that down-regulation results from proteolytic degradation of receptors after their endocytosis and delivery to lysosomes (Perkins et al., 1991; Ferguson et al., 1996; Bohm et al., 1997) . If this model is correct, then internalization should obviously be required for down-regulation to occur. One possible explanation for the ability of our internalization-defective receptors to down-regulate normally is that these mutated receptors do in fact internalize, but they do so at a rate that is too slow to detect in our assays. In this regard, it should be emphasized that internalization is measured after short-term (30-min) exposure to agonist, whereas down-regulation is measured after much longer (24-h) agonist treatment. Thus an undetectably low rate of internalization occurring over a 24-h period could perhaps provide sufficient internalized receptors to allow the normal extent of downregulation. If this were the case, we would anticipate that down-regulation might occur more slowly for the internalization-defective receptors, but we have not observed this in preliminary experiments. The other possibility is that downregulation does in fact occur by a mechanism that is independent of receptor internalization. This would require the development of new hypotheses for down-regulation, and our mutated receptors would be useful for exploring various alternate mechanisms.
The failure of the Tr363 construct to generate receptors that were competent for either radioligand binding or signal generation, coupled with the normal expression, binding, and function of the Tr366 receptor, suggests that the 364-to-366 region of the receptor is critical for normal receptor expression. The presence and/or palmitoylation of Cys365 may be Fig. 3 . Internalization and down-regulation properties of wild-type and deletion-and substitution-mutated ␣ 1B ARs. Loss of ice binding, gradient shift, and down-regulation were all determined as described in the legend to Fig. 2 . In each panel, the values for the wild-type receptor (Wt515) are presented on the far left and far right and as the horizontal dashed line for ease of comparison. All values are the mean Ϯ S.E.; the numbers above each bar represent the total number of determinations and the number of different clones tested, respectively. The asterisk indicates that the value for the mutated receptor is significantly different from the corresponding value for the wild-type receptor, P Ͻ .05.
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at ASPET Journals on September 8, 2017 molpharm.aspetjournals.org important for normal ␣ 1B AR expression, because truncation of both ␤ 2 ARs (Dixon et al., 1987) and ␣ 2 ARs (Kennedy and Limbird, 1994) on the membrane-proximal side of their palmitoylation sites prevented receptor expression. Truncation after Leu363 could also interfere with the function of the "dihydrophobic" Ile-Leu sequence at residues 362 and 363, corresponding to a motif required for proper cell surface delivery of V 2 vasopressin receptors (Schulein et al., 1998) . Together these studies implicate the sequences surrounding and including the potential palmitoylation sites as being critical for regulation of receptor expression, both for proper expression of newly synthesized receptors and for the decreased expression that occurs during down-regulation.
In summary, we have generated and characterized receptors that internalize and down-regulate normally (Tr449, Tr425), identifying regions of the receptor not critical for either process; receptors that internalize normally but are defective in down-regulation , C367A, S369A), identifying residues selectively involved in down-regulation; receptors that are defective in internalization but down-regulate normally (Tr402, Tr380, ), identifying a region critical for internalization and indicating that internalization may not be required for down-regulation; and a receptor defective in both internalization and down-regulation (Tr366). These receptor constructs should prove useful for elucidating in greater detail the molecular mechanisms regulating both the expression and the localization of ␣ 1B ARs, with the results of likely relevance to other GPCRs as well.
